Your browser is no longer supported. Please, upgrade your browser.
Settings
LPTX Leap Therapeutics, Inc. daily Stock Chart
LPTX [NASD]
Leap Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.33 Insider Own20.06% Shs Outstand52.44M Perf Week4.86%
Market Cap113.90M Forward P/E- EPS next Y-0.59 Insider Trans17.45% Shs Float44.00M Perf Month0.52%
Income-39.80M PEG- EPS next Q-0.13 Inst Own60.20% Short Float1.86% Perf Quarter-2.51%
Sales0.80M P/S142.37 EPS this Y10.00% Inst Trans99.19% Short Ratio1.02 Perf Half Y52.76%
Book/sh1.14 P/B1.70 EPS next Y23.40% ROA-134.70% Target Price- Perf Year30.20%
Cash/sh1.11 P/C1.75 EPS next 5Y-2.49% ROE-195.10% 52W Range0.57 - 3.18 Perf YTD73.21%
Dividend- P/FCF- EPS past 5Y-12.40% ROI- 52W High-38.05% Beta1.64
Dividend %- Quick Ratio9.50 Sales past 5Y- Gross Margin- 52W Low243.92% ATR0.12
Employees24 Current Ratio9.50 Sales Q/Q- Oper. Margin- RSI (14)54.65 Volatility7.21% 6.45%
OptionableNo Debt/Eq0.00 EPS Q/Q66.00% Profit Margin- Rel Volume0.60 Prev Close1.94
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume800.63K Price1.97
Recom1.60 SMA207.21% SMA502.50% SMA2003.56% Volume478,191 Change1.55%
Jun-29-20Initiated Piper Sandler Overweight $6
Feb-11-20Initiated Robert W. Baird Outperform $6
Nov-15-19Downgrade Raymond James Outperform → Mkt Perform
Sep-13-19Resumed Raymond James Outperform
Mar-07-17Initiated Ladenburg Thalmann Buy $18
Sep-21-20 07:00AM  
Sep-09-20 07:00AM  
Aug-24-20 07:00AM  
Aug-20-20 10:51AM  
Aug-13-20 07:00AM  
Jul-20-20 03:30PM  
Jun-29-20 10:04AM  
Jun-25-20 04:05PM  
Jun-22-20 04:05PM  
Jun-18-20 09:00AM  
Jun-17-20 04:01PM  
Jun-15-20 09:58AM  
08:32AM  
Jun-12-20 11:19AM  
Jun-11-20 04:06PM  
04:05PM  
May-16-20 10:23AM  
May-14-20 07:00AM  
Apr-23-20 07:00AM  
Apr-07-20 12:25PM  
Mar-18-20 07:00AM  
Mar-16-20 07:00AM  
Jan-23-20 07:00AM  
Jan-07-20 04:05PM  
Jan-06-20 08:25AM  
Jan-03-20 02:11PM  
08:53AM  
Nov-15-19 10:09AM  
Nov-14-19 07:00AM  
Sep-27-19 12:08PM  
Sep-26-19 05:42AM  
Sep-19-19 03:10PM  
Sep-17-19 07:00AM  
Sep-04-19 07:00AM  
Aug-09-19 07:00AM  
Aug-06-19 07:00AM  
Jul-25-19 07:00AM  
Jul-11-19 08:00AM  
Jun-11-19 07:00AM  
May-26-19 09:36AM  
May-15-19 07:00AM  
Apr-03-19 07:00AM  
Apr-01-19 04:05PM  
Mar-18-19 07:00AM  
Mar-11-19 03:10PM  
Mar-08-19 07:00AM  
Feb-05-19 06:15PM  
01:29PM  
Feb-01-19 09:28AM  
Jan-31-19 04:32PM  
Jan-30-19 08:30AM  
Jan-29-19 08:10AM  
Jan-14-19 07:00AM  
Dec-14-18 07:00AM  
Nov-09-18 07:05AM  
07:00AM  
Oct-21-18 06:45AM  
Oct-17-18 09:00AM  
Oct-08-18 06:35PM  
Sep-25-18 07:00AM  
Aug-30-18 04:05PM  
Aug-22-18 07:40AM  
Aug-08-18 07:00AM  
Jul-23-18 07:30AM  
Jun-13-18 07:55AM  
07:00AM  
May-11-18 07:00AM  
May-10-18 08:50AM  
Apr-16-18 09:00AM  
Mar-28-18 08:00AM  
Mar-27-18 04:05PM  
Mar-23-18 09:00AM  
Mar-22-18 04:05PM  
Mar-21-18 07:00AM  
Mar-14-18 05:00PM  
Mar-07-18 07:00AM  
Feb-06-18 07:00AM  
Jan-16-18 07:00AM  
Nov-15-17 09:57AM  
07:00AM  
Nov-13-17 07:00AM  
Sep-19-17 07:00AM  
Sep-08-17 07:00AM  
Aug-11-17 07:00AM  
Jun-26-17 07:00AM  
Jun-24-17 05:00PM  
Jun-21-17 09:07AM  
Jun-01-17 07:00AM  
May-17-17 05:17PM  
May-12-17 07:00AM  
Apr-20-17 12:00PM  
Apr-03-17 07:00AM  
Mar-31-17 04:36PM  
Mar-29-17 07:00AM  
Mar-07-17 07:00AM  
06:53AM  
Mar-01-17 06:40PM  
Feb-09-17 09:12AM  
Feb-03-17 08:00AM  
Jan-28-17 01:04PM  
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerJun 22Buy2.001,750,0003,500,0008,476,496Jun 24 07:00 PM